EP 1012334 A1 20000628 - COMPOSITIONS AND METHODS FOR DETERMINING ANTI-VIRAL DRUG SUSCEPTIBILITY AND RESISTANCE AND ANTI-VIRAL DRUG SCREENING
Title (en)
COMPOSITIONS AND METHODS FOR DETERMINING ANTI-VIRAL DRUG SUSCEPTIBILITY AND RESISTANCE AND ANTI-VIRAL DRUG SCREENING
Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BESTIMMUNG VON ANTI-VIRALER WIRKSTOFF SUSZEPTIBILITÄT UND RESISTENZ SOWIE ANTI-VIRALES WIRKSTOFF-SCREENING
Title (fr)
COMPOSITIONS ET PROCEDES PERMETTANT DE DETERMINER LA SENSIBILITE ET LA RESISTANCE VIS-A-VIS DE MEDICAMENTS ANTIVIRAUX, ET CRIBLAGE DE MEDICAMENTS ANTIVIRAUX
Publication
Application
Priority
- US 9815967 W 19980730
- US 90350797 A 19970730
Abstract (en)
[origin: WO9906597A1] This invention provides a method for determining susceptibility for an HCV or HCMV anti-viral drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell, and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a-c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a-c); at steps (b-c); or at step (c). This invention also provides a method for determining HCV or HCMV anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-viral drug susceptibility of the same patient at a later time; and (c) comparing the anti-viral drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-viral drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient. This invention also provides a method for evaluating the biological effectiveness of a candidate HCV or HCMV anti-viral drug compound. Compositions including resistance test vectors comprising a patient-derived segment comprising an HCV or HCMV gene and an indicator gene and host cells transformed with the resistance test vectors are provided.
IPC 1-7
IPC 8 full level
C12N 5/10 (2006.01); C12N 15/09 (2006.01); C12Q 1/68 (2006.01); C12Q 1/70 (2006.01); G01N 33/15 (2006.01); G01N 33/50 (2006.01)
CPC (source: EP KR)
C12Q 1/68 (2013.01 - KR); C12Q 1/6881 (2013.01 - EP); C12Q 1/6897 (2013.01 - EP); C12Q 1/701 (2013.01 - EP); C12Q 1/707 (2013.01 - EP); C12Q 2600/136 (2013.01 - EP); C12Q 2600/156 (2013.01 - EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9906597 A1 19990211; AU 8897698 A 19990222; CA 2298102 A1 19990211; EP 1012334 A1 20000628; EP 1012334 A4 20041229; JP 2001512036 A 20010821; KR 20010022420 A 20010315
DOCDB simple family (application)
US 9815967 W 19980730; AU 8897698 A 19980730; CA 2298102 A 19980730; EP 98940779 A 19980730; JP 2000505336 A 19980730; KR 20007001002 A 20000128